IDEXX Laboratories
Company History
From humble beginnings in 1984 with less then a dozen employees, IDEXX Corporation has grown into a multi-national company with more then 3,000 employees worldwide. Based in Westbrook, Maine this biotech company generated more $600 million in total revenue in 2005, a 16% increase over fiscal 2004. IDEXX produces equipment and software for use in veterinary offices including in-house diagnostic machinery and testing kits. Equipment, developed by IDEXX allows veterinarians to obtain immediate results from diagnostic tests that were once sent to off-site laboratories. "In addition to the veterinary market, IDEXX also has a leading position in diagnostic tests for poultry, cattle and swine producers and tests for quality and safety of water and milk"(Harkavy, par. 8). Currently, the company operates under three divisions; companion animal group (veterinary services), water and food diagnostics. Their forecast for sales in 2007 is planned to be about $700 - $710 million (IDEXX, 1).
Financials
IDEXX Laboratories is currently trading at 82.27. The 52 week high/ low is the highest and lowest price the stock has traded in the past twelve months. Investors see the highest and lowest indicator as a very important factor. A stock trading at a low might signal a bargain after retreating from its high. Investors, of course will conduct further analysis to view other indicators, but the high/low indicator can still serve as a signal that warrants deeper investigation. IDEXX laboratories have a 52 week high of 86.74 and a 52 week low of 52.94.
Outstanding shares are all the stocks that are currently held by investors including the restricted shares that are owned by the organizations on the inside as...
... middle of paper ...
...inue its pattern of financial growth, the outlook for this organization is a strong and prosperous one. Meeting the 2006 goals of $700 to $710 million in revenues is a key factor to this analysis. IDEXX should continue to set goals that translate to increased yearly revenues and profits.
References
Harkavy, Jerry (Jan. 19, 2006) $100 Million Expansion to Create up to 500 Jobs.
Boston.com News. Retrieved April 16, 2006 from: http://www.boston.com/news/local/maine/articles/2006/01/19/100_million_expansion_to_create_up_to_500_jobs/
IDEXX.com. (2006). IDEXX Laboratories announces fourth quarter results. Retrieved
April 16, 2006 from
http://www.idexx.com/aboutidexx/pressroom/releases/20054qrter.jsp
Nasdaq.com (2006) IDEXX Quote Summary. Retrieved April 15, 2006 from
http://quotes.nasdaq.com/asp/summaryquote.asp?symbol=IDXX%60&selected=IDXX%60
The turnover of the company in 2008 was $15,627 million, gradually decreased in 2009 to $14,552 million which again decreased in 2010 to $13,772 million. We can see a gradual drop in the turnover.
Bristol-Myers Squibb is a worldwide health and personal care company with major businesses in medicines, beauty care, nutritionals, and medical devices. BMS is a leader in innovative therapies for cardiovascular, metabolic and infectious diseases, central nervous system and dermatalogical disorders, and cncer. They are also leaders in consumer medicine, orthopaedic devices, ostomy care, wound management, nutritional supplements, infant formulas, and hair and skin care products.Some of the very well known products manufactured by Bristol-Myers Sqibb are Bufferin, Excederin, Enfamil, Clairol, and Sea Breeze. Another large part of BMS is their research and development of new pharmecutical products. Their annual budget for research and development is in excess of one billion dollars.
Med-Pharmex Incorporated is known nationally and abroad as a pharmaceutical manufacturer of animal-related products. Before gaining fame worldwide, the business began its journey to success as a small lab in 1983, which slowly grew over time. Since then, the company maintains its main goal, and that is to produce drugs that promote the health of companion animals, such as dogs, cats, and horses, as well as food-producing animals, such as pork and chickens. To ensure legal responsibility, the company’s manufacturing process is examined by the United States Food and Drug Administration (FDA). Med-Pharmex works closely with veterinary clinics who purchase their life-saving drugs and represent them in the market. Despite manufacturing drugs, the
Exxon Mobile (NYSE: XOM) didn’t have a good start for the year, but the fourth-quarter results helped the company’s share to rise nearly 7% despite not so exciting financial performance. Its shares are now up approximately 3% since year-to-date. The company for the quarter reported earnings of $0.67 per share, a slump of 57% as compared to earnings of $1.56 per share in the fourth-quarter of 2014.
Based on the Terminal P/E and the cost of equity I made a sensitivity analysis chart through which I came up with a price of $33.37. This chart shows the different price ranges of the stock which could be possible if the Terminal P/E went higher or lower compared to the Cost of Equity.
First, this text will discuss some background on Labcorp to form a better understanding of the business, and the practices used. Labcorp is one of the largest clinical Laboratories in the world, which includes many wholly owned subsidiaries. The Laboratory Corporation of America (2013) website LabCorp has over 220,000 clients and process over 400,000 samples per day. LabCorp uses an innovative clinical laboratory processing, referral, and specimen testing information systems to create fluent, and easy to use specimen processing and testing. This process has developed through time, and LabCorp has grown into a robust multi- laboratory testing facilities through the buyout, and absorption of numerous specialty laboratories. As the buyout of subsidiaries has been a large part of the growth of this business, information technology had to grow along side, as the connection between all sites became critical for survival, to keep the stance of a premier multifunctional Laboratory tycoon (Laboratory Corporation of America, 2013).
One of the most frequent questions we get asked is: How much is Isagenix? The answer is dependent on several factors such as the country website you are ordering from, whether the products you are ordering are individual or packaged products, and if you are making a purchase as an associate, as a preferred customer, or as a full retail price customer. Our website is conveniently assessable to Isagenix customers throughout Canada, the United States, and in Puerto Rico.
There are articles online that discuss the benefits of buying Exelixis Inc. right now, considering how low of a price poi...
The stock price is currently 103.31, down from a recent high of 121.50. The P/E ratio is declining at 28 and beta at .67, which is expected to grow closer to 1.0. A recent earnings surprise last December yielded a 15% difference from the lower expectations and the latest earnings reports late last month also surprised investors. Estimates for the 2000 fiscal year are being raised by a large majority of analyst who believe that earnings per share will increase and the stock price will reach close to 150.
After conducting a basic 10 year financial analysis of the company, it has become evident that even with a highly competitive market structure they are able to improve on their performance. Ranging from 2004 to 2013 financial information, the company has shown a significant increase in their sales revenue roughly $3865 million sales in 2004 to almost four time that valuing $12970 million in 2013, which was an “increase of 10.4% over the 53 week prior year” The company’s growth strategy has been to diversify its product market and make them...
From June 2004 to June 2005, Microsoft saw a 33% growth in net income. However, from June 2005 to June 2006, growth decreased to 2%. Investors consider net income to be the leading indicator for a stock price. To illustrate how the changes in net income affect stock prices, a time line is shown below.
Common stock is a term that is synonymous with investing; it is ownership in a public company. The stock owner is granted voting rights in addition the ability to receive dividends. It is a common terminology that is heard frequently in terms of the daily performance of the stock market whether it was up or down.
The most interesting company to compare Inditex is The Gap. Although The Gap has much higher revenues than Inditex (almost five times Inditex), it incurred a net loss, as opposed to Inditex, which achieved a 23%, return in investment. This is due to the extremely high costs of good sold for The Gap. This could be caused -at least partially- by the complete outsourcing of the production. They do not have enough control over the production costs. Although The Gap has larger market share than Inditex and has equity almost double that of Inditex, Inditex is much more profitable.
Byte Products, Inc., headquartered in the midwestern United States, is regarded as one of the largest volume supplier for the production of electronic components used in personal computers. Byte Products, Inc., was a privately owned firm that has now entered to be a publicly traded company. The majority of the stockholders are the initial owners of Byte, when it was still privately owned. The products that Byte produces are primarily found in computers used for business and engineering applications. Byte Products, Inc., has been the leader in this industry for the past six year with consistent yearly revenues of 12% and total sales of approximately $265 million. Byte also has 32% of the market share.
has grown into a $49.7 billion corporation by clearly focusing on the goal of enabling commerce around the globe.